The Hamburg biotech company Evotec AG and PlasmidFactory, located in Bielefeld, have now signed an agreement by which the pDG/pDP plasmids manufactured by PlasmidFactory will be used in the platform established by Evotec for the manufacture of AAVs.
For some years now PlasmidFactory has had an exclusive, worldwide licence from the German Cancer Research Centre, Heidelberg (DKFZ), for the manufacture, distribution and use of the helper & packaging plasmids of the pDG and pDP family. These are used in a 2-plasmid system to manufacture adeno-associated viruses (AAVs). This means only two components are needed: a plasmid with the gene to be transferred and the corresponding pDG/pDP plasmid, which contains all the information for the propagation and packaging of AAVs (the so-called “helper & packaging” functions). The production process for AAV vectors, whose use in gene therapy is increasing significantly, is thereby considerably simplified compared to older systems with three plasmids. The plasmids of the pDG/pDP families are available from PlasmidFactory in various serotypes in corresponding quality grades for research purposes up through AAV production in compliance with GMP.
The plasmids manufactured by PlasmidFactory are used by Evotec to produce recombinant AAV vectors for research purposes, especially in the field of neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Huntington’s diseases. Priority is given to the validation of therapeutic targets and the development of cellular test models for the identification of new control structures (agent identification and development).
For some years now PlasmidFactory has had an exclusive, worldwide licence from the German Cancer Research Centre, Heidelberg (DKFZ), for the manufacture, distribution and use of the helper & packaging plasmids of the pDG and pDP family. These are used in a 2-plasmid system to manufacture adeno-associated viruses (AAVs). This means only two components are needed: a plasmid with the gene to be transferred and the corresponding pDG/pDP plasmid, which contains all the information for the propagation and packaging of AAVs (the so-called “helper & packaging” functions). The production process for AAV vectors, whose use in gene therapy is increasing significantly, is thereby considerably simplified compared to older systems with three plasmids. The plasmids of the pDG/pDP families are available from PlasmidFactory in various serotypes in corresponding quality grades for research purposes up through AAV production in compliance with GMP.
The plasmids manufactured by PlasmidFactory are used by Evotec to produce recombinant AAV vectors for research purposes, especially in the field of neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Huntington’s diseases. Priority is given to the validation of therapeutic targets and the development of cellular test models for the identification of new control structures (agent identification and development).
